https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Health and Social Characteristics of Clients Reporting Amphetamine Type Substance Use at Entry to Public Alcohol and Other Drug Services in New South Wales, Australia, 2016–2019 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50489 Wed 28 Feb 2024 15:28:31 AEDT ]]> N-acetylcysteine (NAC) for methamphetamine dependence: A randomised controlled trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48692 Tue 28 Mar 2023 20:45:40 AEDT ]]> Investigating the links between lower iron status in pregnancy and respiratory disease in offspring using murine models https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45342 Thu 27 Oct 2022 15:17:41 AEDT ]]> Transforming growth factor (TGF) β₁ and Smad signalling pathways: a likely key to EMT-associated COPD pathogenesis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33298 Thu 04 Oct 2018 09:48:22 AEST ]]> Clinical and demographic characteristics of people who smoke versus inject crystalline methamphetamine in Australia: Findings from a pharmacotherapy trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49563 0.05). After adjustment for demographic differences, participants who smoked had lower craving [b (SE) = −1.1 (0.5), P = 0.021] and were less likely to report psychotic symptoms [b (SE) = −1.8 (0.7), P = 0.013] or antidepressant use [b (SE) = −1.1 (0.5), P = 0.022]. Discussion and Conclusions: Smoking crystalline methamphetamine is associated with a younger less marginalised demographic profile than injecting methamphetamine, but a similarly severe clinical profile.]]> Mon 22 May 2023 09:20:09 AEST ]]> Substance use, socio-demographic characteristics, and self-rated health of people seeking alcohol and other drug treatment in New South Wales: baseline findings from a cohort study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51584 Mon 11 Sep 2023 14:36:30 AEST ]]> The iron-chelator, N,N’-bis (2-hydroxybenzyl) Ethylenediamine-N,N’-diacetic acid is an effective colistin adjunct against clinical strains of biofilm-dwelling Pseudomonas aeruginosa https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36544 Pseudomonas aeruginosa may be an effective adjunctive for conventional antibiotic treatment against biofilm-dwelling P. aeruginosa. We, therefore, assessed the anti-biofilm activity of N,N’-bis (2-hydroxybenzyl) ethylenediamine-N,N’-diacetic acid (HBED), which is a synthetic hexadentate iron chelator. The effect of HBED was studied using short-term (microtitre plate) and longer-term (flow-cell) biofilm models, under aerobic, anaerobic, and microaerobic (flow-cell) conditions and in combination with the polymyxin antibiotic colistimethate sodium (colistin). HBED was assessed against strains of P. aeruginosa from patients with cystic fibrosis and the reference strain PAO1. HBED inhibited growth and biofilm formation of all clinical strains under aerobic and anaerobic conditions, but inhibitory effects against PAO1 were predominantly exerted under anaerobic conditions. PA605, which is a clinical strain with a robust biofilm-forming phenotype, was selected for flow-cell studies. HBED significantly reduced biomass and surface coverage of PA605, and, combined with colistin, HBED significantly enhanced the microcolony killing effects of colistin to result in almost complete removal of the biofilm. HBED combined with colistin is highly effective in vitro against biofilms formed by clinical strains of P. aeruginosa.]]> Mon 01 Jun 2020 17:28:29 AEST ]]> Progress towards Elimination of Hepatitis C Infection among People Who Inject Drugs in Australia: The ETHOS Engage Study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49510 Fri 19 May 2023 16:56:03 AEST ]]>